摘要
目的比较非布司他与别嘌醇治疗痛风及高尿酸血症差异,探讨非布司他应用价值。方法痛风伴高尿酸血症患者共100例,随机分为非布司他组及别嘌醇组,各50例,两组均给予健康宣教和饮食干预,有合并症的患者根据其具体情况给予对症治疗,先给予秋水仙碱治疗,其后非布司他组患者口服非布司他40 mg,每天1次;别嘌醇组予别嘌醇100 mg,每天3次。结果治疗前两组尿酸水平(524.67±80.15)μmol/L vs.(519.58±79.27)μmol/L,差异无统计学意义(P>0.05);治疗4周、8周以后两组尿酸水平均有所下降,但非布司他组4周后(402.38±52.39)μmol/L、8周后(380.25±47.76)μmol/L均低于别嘌醇组的(463.23±48.34)μmol/L、(427.24±45.68)μmol/L(P<0.05);非布司他组治疗总有效98.00%,高于别嘌醇组的80.00%(P<0.05);非布司他组药物不良反应6.00%,低于别嘌醇组的20.00%(P<0.05)。结论痛风合并高尿酸血症是一种常见的病程长、危害大的疾病,非布司他的临床疗效较为可靠,降尿酸的作用较为显著,值得推广应用。
Objective Compared the difference between febuxostat and allopurinol in treating gout and hyperuricemia. Discuss the application value of febuxostat. Methods A total of 100 patients were divided into febuxostat group and allopurinol group randomly,each group has 50 patients.Two groups were both given health education and dietary intervention.Symptomatic treatment are applied for the patients with complications. Both groups were given colchicine treatment first, after the febuxostat group were treated with febuxostat 40 mg a day and the allopurinol group was treated with allopurinol l00 mg 3 times a day. Results Before treatment, there was no difference（P〉0.05）between two groups in uric acid level（524.67±80.15） μmol/L vs.（519.58±79.27）μmol/L; After 4 weeks and 8 weeks, the uric acid levels of the two groups decreased,but the uric acid levels of the febuxostat group was（402.38±52.39） μmol/L after 4 weeks, after 8 weeks was（380.25±47.76） μmol/L, which were lower than the allopurinol group（463.23±48.34）μmol/L,（427.24±45.68）μmol/L（P〈0.05）; The figure for total effective treatment of the febuxostat group was 98.00%, higher than the allopurinol group 80.00%（P〈0.05）; drug adverse reaction accounts for 6.00% in febuxostat group, lower than the allopurinol group 20.00%（P〈0.05） Conclusion Gout complicated with hyperuricemia is a common disease with long course and great harm. The clinical efficacy of febuxostat is reliable, and the effect of reducing uric acid is remarkable. It is worth popularizing in the future.
作者
施红裕
SHI Hong-yu(Department of Nephrology,the Branch Affliated Hospital of Nantong University,Jiangsu Nantong 226001,China.)
出处
《中国处方药》
2018年第5期11-13,共3页
Journal of China Prescription Drug
